Literature DB >> 29366841

Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease.

David J Gracie1, Elspeth A Guthrie2, P John Hamlin3, Alexander C Ford3.   

Abstract

BACKGROUND & AIMS: Inflammatory bowel diseases (IBD) are associated with mood disorders, such as anxiety or depression, but it is not clear whether one contributes to development of the other, or if the interaction is bi-directional (anxiety or depression contributes to the progression of IBD, and IBD affects psychological health). We performed a 2-year longitudinal prospective study of patients in secondary to care investigate the bi-directionality of IBD and mood disorders.
METHODS: We collected data from 405 adult patients with a diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) from November 2012 through June 2017. Demographic features, subtypes of IBD, treatments, symptoms, somatization, and fecal level of calprotectin were recorded at baseline. IBD activity was determined at baseline and after the follow-up period (2 years or more) using the Harvey-Bradshaw Index for CD and the Simple Clinical Colitis Activity Index for UC (scores ≥5 used to define disease activity). Anxiety and depression data were collected using the Hospital Anxiety and Depression Scale (HADS), at baseline and after the follow-up period. Objective markers of disease activity, including glucocorticosteroid prescription or flare of disease activity, escalation of therapy, hospitalization secondary to IBD activity, and intestinal resection during follow-up were assessed via case note review. A brain-gut direction of disease activity was defined as development of new IBD activity in patients with quiescent IBD and abnormal HADS scores at baseline. A gut-brain direction of disease activity was defined by subsequent development of abnormal HADS scores in patients with active IBD and normal HADS scores at baseline. We performed multivariate Cox regression controlling for patient characteristics and follow-up duration.
RESULTS: Baseline CD or UC disease activity were associated with an almost 6-fold increase in risk for a later abnormal anxiety score (hazard ratio [HR], 5.77; 95% CI, 1.89-17.7). In patients with quiescent IBD at baseline, baseline abnormal anxiety scores were associated with later need for glucocorticosteroid prescription or flare of IBD activity (HR, 2.08; 95% CI, 1.31-3.30) and escalation of therapy (HR, 1.82; 95% CI, 1.19-2.80). These associations persisted when normal IBD activity index scores and fecal level of calprotectin <250 μg/g were used to define quiescent disease at baseline.
CONCLUSIONS: In a 2-year study of patients with CD or UC, we found evidence for bi-directional effects of IBD activity and psychological disorders. Patients with IBD should be monitored for psychological well-being.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease Progression; Enteric Nervous System; Gut–Brain Axis; Pathogenesis

Mesh:

Substances:

Year:  2018        PMID: 29366841     DOI: 10.1053/j.gastro.2018.01.027

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  76 in total

1.  Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance and Healthcare Utilization in Patients with Inflammatory Bowel Disease.

Authors:  Sumedha V Chablani; Claudia Ramos-Rivers; David G Binion; Eva Szigethy
Journal:  Dig Dis Sci       Date:  2018-07-19       Impact factor: 3.199

Review 2.  AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.

Authors:  Jean-Frederic Colombel; Andrea Shin; Peter R Gibson
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

3.  Does Reverse Causality Underlie the Temporal Relationship Between Depression and Crohn's Disease?

Authors:  Lawrence S Gaines; James C Slaughter; David A Schwartz; Dawn B Beaulieu; Sara N Horst; Robin L Dalal; Elizabeth A Scoville; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2020-02-11       Impact factor: 5.325

Review 4.  Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.

Authors:  Amir Abdoli; Hoda Mirzaian Ardakani
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

Review 5.  Vagus Nerve Stimulation at the Interface of Brain-Gut Interactions.

Authors:  Bruno Bonaz; Valérie Sinniger; Sonia Pellissier
Journal:  Cold Spring Harb Perspect Med       Date:  2019-08-01       Impact factor: 6.915

6.  Partitioned glioma heritability shows subtype-specific enrichment in immune cells.

Authors:  Quinn T Ostrom; Jacob Edelson; Jinyoung Byun; Younghun Han; Ben Kinnersley; Beatrice Melin; Richard S Houlston; Michelle Monje; Kyle M Walsh; Christopher I Amos; Melissa L Bondy
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

Review 7.  Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis.

Authors:  Hannibal Person; Laurie Keefer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-12-14       Impact factor: 5.067

8.  Predicting the development of psychological morbidity in inflammatory bowel disease: a systematic review.

Authors:  Anna B Hoogkamer; Alenka J Brooks; Georgina Rowse; Alan J Lobo
Journal:  Frontline Gastroenterol       Date:  2020-03-16

9.  Association between antidepressant medication use and steroid dependency in patients with ulcerative colitis: a population-based study.

Authors:  Jonathan Blackwell; Christopher Alexakis; Sonia Saxena; Hanna Creese; Alex Bottle; Irene Petersen; Matthew Hotopf; Richard C G Pollok
Journal:  BMJ Open Gastroenterol       Date:  2021-05

10.  Mindfulness-Based Virtual Reality Intervention for Children and Young Adults with Inflammatory Bowel Disease: A Pilot Feasibility and Acceptability Study.

Authors:  Anava A Wren; Nicole Neiman; Thomas J Caruso; Samuel Rodriguez; Katherine Taylor; Martine Madill; Hal Rives; Linda Nguyen
Journal:  Children (Basel)       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.